Clinical Trial Update: Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD [Phase 1]

View source ↗

Summary

A Phase 1 trial update describes evaluating a combination of ruxolitinib and fostamatinib for steroid-refractory chronic graft-versus-host disease, with recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Fostamatinib (fostamatinib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Stefanie Sarantopoulos, MD, PhD. | Conditions: Chronic Graft Versus Host Disease | Phase 1 | Status: RECRUITING